ArticleJournal of translational medicine2025
Development of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) represents a highly malignant form of cancer characterized by molecular heterogeneity and unsatisfactory treatment outcomes, with approximately 50% of patients experiencing local recurrence and distant metastasis following therapy. Given that metastasis is the most critical determinant of OSCC prognosis, enhancing the precision of clinical interventions and identifying therapeutic targets are of paramount importance. In view of this, this study is the first to develop a machine-learning-based prognostic model integrating epithelial-mesenchymal transition (EMT), anoikis, and basement membrane remodeling genes.
methodsWe systematically evaluated 78 algorithm and parameter combinations to identify a robust prognostic model, stratifying patients into High- and Low-risk groups. Kaplan-Meier survival curves and receiver operating characteristic (ROC) analyses were employed to evaluate the predictive performance of this model. Functional enrichment of differentially expressed genes (DEGs) between risk groups revealed key OSCC progression mechanisms. We further analyzed tumor mutation burden, immune microenvironment features, and identified candidate drugs through sensitivity prediction and molecular docking.
resultsThe identified 13-gene prognostic model effectively stratified patients into high- and low-risk groups, demonstrating strong predictive power for overall survival: the high-risk group exhibited worse prognosis. Mutation landscape demonstrated significant genetic variability within these model genes, which provided insights into the association between elevated tumor mutational burden and adverse prognostic outcomes. Immune landscape revealed a distinct tumor microenvironment: high-risk group exhibited altered immune cell infiltration, along with increased tumor purity, reduced ESTIMATE score and poorer anticipated response to immunotherapy. Finally, seven promising therapeutic candidates were identified through integrated computational drug screening.
conclusionWe developed and validated a 13-gene prognostic model that integrates metastasis-related processes, improves survival prediction, and identifies therapeutic opportunities in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.